RFX1: a promising therapeutic arsenal against cancer

1.

Wang K-R, Nemoto T, Yokota Y. RFX1 Mediates the serum-induced immediate early response of Id2 gene expression. J Biol Chem. 2007;282(36):26167–77. https://doi.org/10.1074/jbc.M703448200.CrossRefPubMed

2.

Feng C, Zhang Y, Yin J, Li J, Abounader R, Zuo Z. Regulatory factor X1 is a new tumor suppressive transcription factor that acts via direct downregulation of CD44 in glioblastoma. Neuro Oncol. 2014;16:1078–85.CrossRef

3.

Watts JA, Zhang C, Klein-Szanto AJ, Kormish JD, Fu J, Zhang MQ, et al. Study of FoxA pioneer factor at silent genes reveals Rfx-repressed enhancer at Cdx2 and a potential indicator of esophageal adenocarcinoma development. Reid B, editor. PLoS Genet . 2011;7(9):1002277. Doi: https://doi.org/10.1371/journal.pgen.1002277.

4.

Wang J-B, Liu F-H, Chen J-H, Ge H-T, Mu L-Y, Bao H-B, et al. Identifying survival-associated modules from the dysregulated triplet network in glioblastoma multiforme. J Cancer Res Clin Oncol. 2017;143(4):661–71. https://doi.org/10.1007/s00432-016-2332-z.CrossRefPubMed

5.

Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, et al. A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci. 2004;101(39):14228–33. https://doi.org/10.1073/pnas.0400067101.CrossRefPubMed

6.

Adorno-Cruz V, Kibria G, Liu X, Doherty M, Junk DJ, Guan D, et al. Cancer stem cells: targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance. Cancer Res. 2015;75(6):924–9. https://doi.org/10.1158/0008-5472.CAN-14-3225.CrossRefPubMedPubMedCentral

7.

Hsu Y-C, Liao W-C, Kao C-Y, Chiu I-M. Regulation of FGF1 gene promoter through transcription factor RFX1. J Biol Chem. 2010;285(18):13885–95. https://doi.org/10.1074/jbc.M109.081463.CrossRefPubMedPubMedCentral

8.

Lee C-C, Ho H-C, Su Y-C, Lee M-S, Hung S-K, Lin C-H. MCP1-Induced epithelial-mesenchymal transition in head and neck cancer by AKT activation. Anticancer Res. 2015;35(6):3299–306. https://doi.org/10.3389/fmicb.2018.01019/full.CrossRefPubMed

9.

Chen L, Smith L, Johnson MR, Wang K, Diasio RB, Smith JB. Activation of protein kinase C induces nuclear translocation of RFX1 and down-regulates c- myc via an Intron 1 X Box in undifferentiated leukemia HL-60 Cells. J Biol Chem. 2000;275(41):32227–33. https://doi.org/10.1074/jbc.M002645200.CrossRefPubMed

10.

Su J-C, Tseng P-H, Hsu C-Y, Tai W-T, Huang J-W, Ko C-H, et al. RFX1-dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells. Oncotarget. 2014;5(13):4909–19. https://doi.org/10.18632/oncotarget.2054.CrossRefPubMedPubMedCentral

11.

Reith W, Herrero-Sanchez C, Kobr M, Silacci P, Berte C, Barras E, et al. MHC class II regulatory factor RFX has a novel DNA-binding domain and a functionally independent dimerization domain. Genes Dev. 1990;4(9):1528–40. https://doi.org/10.1101/gad.4.9.1528.CrossRefPubMed

12.

Pugliatti L, Derré J, Berger R, Ucla C, Reith W, Mach B. The genes for MHC class II regulatory factors RFX1 and RFX2 are located on the short arm of chromosome 19. Genomics. 1992. 13(4):1307–10. https://linkinghub.elsevier.com/retrieve/pii/088875439290052T.

13.

Qiu L, Wang J, Chen M, Chen F, Tu W. Exosomal microRNA-146a derived from mesenchymal stem cells increases the sensitivity of ovarian cancer cells to docetaxel and taxane via a LAMC2-mediated PI3K/Akt axis. Int J Mol Med. 2020;46(2):609–20. https://doi.org/10.3892/ijmm.2020.4634.CrossRefPubMedPubMedCentral

14.

Du P, Gao K, Cao Y, Yang S, Wang Y, Guo R, et al. RFX1 downregulation contributes to TLR4 overexpression in CD14+ monocytes via epigenetic mechanisms in coronary artery disease. Clin Epigenetics. 2019;11(1):44. https://doi.org/10.1186/s13148-019-0646-9.CrossRefPubMedPubMedCentral

15.

Zhao M, Tan Y, Peng Q, Huang C, Guo Y, Liang G, et al. IL-6/STAT3 pathway induced deficiency of RFX1 contributes to Th17-dependent autoimmune diseases via epigenetic regulation. Nat Commun. 2018. 9(1):583. http://www.nature.com/articles/s41467-018-02890-0.

16.

Iwama A, Pan J, Zhang P, Reith W, Mach B, Tenen DG, et al. Dimeric RFX proteins contribute to the activity and lineage specificity of the interleukin-5 receptor α promoter through activation and repression domains. Mol Cell Biol. 1999. 19(6):3940–50. https://mcb.asm.org/content/19/6/3940.

17.

Phi LTH, Sari IN, Yang YG, Lee SH, Jun N, Kim KS, et al. Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment. Stem Cells Int. 2018. 2018:1–16. https://www.hindawi.com/journals/sci/2018/5416923/.

18.

Swoboda P, Adler HT, Thomas JH. The RFX-Type transcription factor DAF-19 regulates sensory neuron cilium formation in C. elegans. Mol Cell. 2000. 5(3):411–21. https://www.sciencedirect.com/science/article/pii/S1097276500804360.

19.

Zajac-Kaye M, Ben-Baruch N, Kastanos E, Kaye FJ, Allegra C. Induction of Myc-intron-binding polypeptides MIBP1 and RFX1 during retinoic acid-mediated differentiation of haemopoietic cells. Biochem J. 2000. 345(3):535. http://www.biochemj.org/bj/345/bj3450535.htm.

20.

Chen YC, Tsai CL, Wei YH, Wu YT, Hsu WT, Lin HC, et al. ATOH1/RFX1/RFX3 transcription factors facilitate the differentiation and characterisation of inner ear hair cell-like cells from patient-specific induced pluripotent stem cells harbouring A8344G mutation of mitochondrial DNA article. Cell Death Dis. 2018

21.

Shibata M, Kanda M, Shimizu D, Tanaka H, Umeda S, Hayashi M, et al. Expression of regulatory factor X1 can predict the prognosis of breast cancer. Oncol Lett. 2017;13(6):4334–40. https://doi.org/10.3892/ol.2017.6005.CrossRefPubMedPubMedCentral

22.

Piasecki BP, Burghoorn J, Swoboda P. Regulatory Factor X (RFX)-mediated transcriptional rewiring of ciliary genes in animals. Proc Natl Acad Sci. 2010;107(29):12969–74. https://doi.org/10.1073/pnas.0914241107.CrossRefPubMed

23.

Emery P, Durand B, Mach B, Reith W. RFX proteins, a novel family of DNA binding proteins conserved in the eukaryotic kingdom. Nucleic Acids Res. 1996. 24(5):803–7. http://www.ncbi.nlm.nih.gov/pubmed/8600444.

24.

Gajiwala KS, Chen H, Cornille F, Roques BP, Reith W, Mach B, et al. Structure of the winged-helix protein hRFX1 reveals a new mode of DNA binding. Nature. 2000. 403(6772):916–21. http://www.nature.com/articles/35002634.

25.

Efimenko E. Analysis of xbx genes in C. elegans. Development. 2005;132(8):1923–34. https://doi.org/10.1242/dev.01775.CrossRefPubMed

26.

Laurençon A, Dubruille R, Efimenko E, Grenier G, Bissett R, Cortier E, et al. Identification of novel regulatory factor X (RFX) target genes by comparative genomics in Drosophila species. Genome Biol. 2007;8(9):R195. https://doi.org/10.1186/gb-2007-8-9-r195.CrossRefPubMedPubMedCentral

27.

Bisgrove BW, Makova S, Yost HJ, Brueckner M. RFX2 is essential in the ciliated organ of asymmetry and an RFX2 transgene identifies a population of ciliated cells sufficient for fluid flow. Dev Biol. 2012; 363(1):166–78. https://linkinghub.elsevier.com/retrieve/pii/S0012160611014503.

28.

Chung M-I, Peyrot SM, LeBoeuf S, Park TJ, McGary KL, Marcotte EM, et al. RFX2 is broadly required for ciliogenesis during vertebrate development. Dev Biol. 2012;363(1):155–65. https://linkinghub.elsevier.com/retrieve/pii/S0012160611014497.

29.

Chen B, Niu J, Kreuzer J, Zheng B, Jarugumilli GK, Haas W, et al. Auto-fatty acylation of transcription factor RFX3 regulates ciliogenesis. Proc Natl Acad Sci. 2018;115(36):E8403–12. https://doi.org/10.1073/pnas.1800949115.CrossRefPubMed

30.

Sugiaman-Trapman D, Vitezic M, Jouhilahti E-M, Mathelier A, Lauter G, Misra S, et al. Characterization of the human RFX transcription factor family by regulatory and target gene analysis. BMC Genomics . 2018;19(1):181. http://www.ncbi.nlm.nih.gov/pubmed/29510665.

31.

Jeong HY, Kim H-J, Kim C-E, Lee S, Choi M-C, Kim S-H. High expression of RFX4 is associated with tumor progression and poor prognosis in patients with glioblastoma. Int J Neurosci. 2020;2:1–8. https://doi.org/10.1080/00207454.2020.1732969.CrossRef

32.

Matsushita H, Uenaka A, Ono T, Hasegawa K, Sato S, Koizumi F, et al. Identification of glioma-specific RFX4-E and -F isoforms and humoral immune response in patients. Cancer Sci. 2005;96(11):801–9. https://doi.org/10.1111/j.1349-7006.2005.00112.x.CrossRefPubMed

33.

Luo W-M, Wang Z-Y, Zhang X. Identification of four differentially methylated genes as prognostic signatures for stage I lung adenocarcinoma. Cancer Cell Int. 2018;18(1):60. https://doi.org/10.1186/s12935-018-0547-6.CrossRefPubMedPubMedCentral

34.

Mills IG. HOXB13, RFX6 and prostate cancer risk. Nat Genet. 2014;46(2):94–5. http://www.nature.com/articles/ng.2881.

35.

Fischer BA, Chelbi ST, Guarda G. Regulatory factor X 7 and its potential link to lymphoid cancers. Trends Cancer. 2020;6(1):6–9. https://linkinghub.elsevier.com/retrieve/pii/S2405803319302341.

36.

Reith W, Ucla C, Barras E, Gaud A, Durand B, Herrero-Sanchez C, et al. RFX1, a transactivator of hepatitis B virus enhancer I, belongs to a novel family of homodimeric and heterodimeric DNA-binding proteins. Mol Cell Biol. 1994;14(2):1230–44. https://doi.org/10.1128/MCB.14.2.1230.CrossRefPubMedPubMedCentral

37.

Katan-Khaykovich Y, Shaul Y. Nuclear import and DNA-binding activity of RFX1. Eur J Biochem. 2001;268(10):3108–16. https://doi.org/10.1046/j.1432-1327.2001.02211.x.CrossRefPubMed

38.

Aftab S, Semenec L, Chu J, Chen N. Identification and characterization of novel human tissue-specific RFX transcription factors. BMC Evol Biol. 2008;8(1):226. https://doi.org/10.1186/1471-2148-8-226.CrossRefPubMedPubMedCentral

39.

Katan-Khaykovich Y, Spiegel I, Shaul Y. The dimerization/repression domain of RFX1 is related to a conserved region of its yeast homologues crt1 and sak1: a new function for an ancient motif 1 1Edited by A. Klug. J Mol Biol. 1999;294(1):121–37. https://linkinghub.elsevier.com/retrieve/pii/S002228369993245X.

40.

Min K, Son H, Lim JY, Choi GJ, Kim J-C, Harris SD, et al. Transcription Factor RFX1 Is Crucial for Maintenance of Genome Integrity in Fusarium graminearum. Eukaryot Cell. 2014;13(3):427–36. https://ec.asm.org/content/13/3/427.

41.

Zaim J, Speina E, Kierzek AM. Identification of New Genes regulated by the Crt1 transcription factor, an effector of the DNA damage checkpoint pathway in Saccharomyces cerevisiae. J Biol Chem. 2005;280(1):28–37. https://doi.org/10.1074/jbc.M404669200.CrossRefPubMed

42.

Garg A, Futcher B, Leatherwood J. A new transcription factor for mitosis: in Schizosaccharomyces pombe, the RFX transcription factor Sak1 works with forkhead factors to regulate mitotic expression. Nucleic Acids Res. 2015;43(14):6874–88. https://doi.org/10.1093/nar/gkv274.CrossRefPubMedPubMedCentral

43.

Senti G, Swoboda P. Distinct Isoforms of the RFX Transcription Factor DAF-19 Regulate Ciliogenesis and Maintenance of Synaptic Activity. Gonzalez-Gaitan M, editor. Mol Biol Cell. 2008;19(12):5517–28. Doi: https://doi.org/10.1091/mbc.e08-04-0416.

44.

Nakayama A, Murakami H, Maeyama N, Yamashiro N, Sakakibara A, Mori N, et al. Role for RFX transcription factors in non-neuronal cell-specific inactivation of the microtubule-associated protein MAP1A promoter. J Biol Chem. 2003;278(1):233–40. https://doi.org/10.1074/jbc.M209574200.CrossRefPubMed

45.

Purvis TL, Hearn T, Spalluto C, Knorz VJ, Hanley KP, Sanchez-Elsner T, et al. Transcriptional regulation of the Alström syndrome gene ALMS1 by members of the RFX family and Sp1. Gene. 2010;460(1–2):20–9. https://linkinghub.elsevier.com/retrieve/pii/S0378111910001332.

46.

Wang B, Qi T, Chen S-Q, Ye L, Huang Z-S, Li H. RFX1 maintains testis cord integrity by regulating the expression of Itga6 in male mouse embryos. Mol Reprod Dev. 2016;83(7):606–14. https://doi.org/10.1002/mrd.22660.CrossRefPubMed

47.

Feng C, Xu W, Zuo Z. Knockout of the regulatory factor X1 gene leads to early embryonic lethality. Biochem Biophys Res Commun. 2009;386(4):715–7. https://linkinghub.elsevier.com/retrieve/pii/S0006291X09012662.

48.

Elkon R, Milon B, Morrison L, Shah M, Vijayakumar S, Racherla M, et al. RFX transcription factors are essential for hearing in mice. Nat Commun. 2015;6(1):8549. http://www.nature.com/articles/ncomms9549.

49.

Xie X, Rigor P, Baldi P. MotifMap: a human genome-wide map of candidate regulatory motif sites. Bioinformatics. 2009;25(2):167–74. https://doi.org/10.1093/bioinformatics/btn605.CrossRefPubMed

50.

Liu XJ, Zhao ZH, Liu XM. Prediction of regulatory factor X1 binding sites in promoters of RNA-binding proteins genes in mouse brain. Arch Iran Med. 2013;16(7):390–6. http://www.ncbi.nlm.nih.gov/pubmed/23808775.

51.

Yan C, Chen H, Bai L. Systematic study of nucleosome-displacing factors in budding yeast. Mol Cell . 2018;71(2):294–305.e4. https://linkinghub.elsevier.com/retrieve/pii/S1097276518304623.

52.

Shin G, Kang TW, Yang S, Baek SJ, Jeong YS, Kim SY. GENT: gene expression database of normal and tumor tissues. Cancer Inform. 2011. https://doi.org/10.4137/CIN.S7226.CrossRefPubMedPubMedCentral

53.

Park S-J, Yoon B-H, Kim S-K, Kim S-Y. GENT2: an updated gene expression database for normal and tumor tissues. BMC Med Genomics. 2019;12(S5):101. https://doi.org/10.1186/s12920-019-0514-7.CrossRefPubMedPubMedCentral

54.

Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, Anderson K. Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol. 2012;9(3):135–43. http://www.ncbi.nlm.nih.gov/pubmed/22349016.

55.

Hornbeck P V., Zhang B, Murray B, Kornhauser JM, Latham V, Skrzypek E. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res . 2015;43(D1):D512–20. http://academic.oup.com/nar/article/43/D1/D512/2439467/PhosphoSitePlus-2014-mutations-PTMs-and.

56.

Agami R, Shaul Y. The kinase activity of c-Abl but not v-Abl is potentiated by direct interaction with RFXI, a protein that binds the enhancers of several viruses and cell-cycle regulated genes. Oncogene. 1998.16(14):1779–88. http://www.nature.com/articles/1201708.

57.

Campbell JL, Pedersen OK. The varieties of capitalism and hybrid success. Comp Polit Stud. 2007;40(3):307–32. https://doi.org/10.1177/0010414006286542.CrossRef

58.

Zhai Y, Chen Y, Li Q, Zhang L. Exploration of the hub genes and miRNAs in lung adenocarcinoma. Oncol Lett. 2019. https://doi.org/10.3892/ol.2019.10478.CrossRefPubMedPubMedCentral

59.

Fabregat I, Malfettone A, Soukupova J. New Insights into the Crossroads between EMT and Stemness in the Context of Cancer. J Clin Med . 2016;5(3):37. http://www.mdpi.com/2077-0383/5/3/37.

60.

Liu Y, Jiang P, Wang G, Liu X, Luo S. Downregulation of RFX1 predicts poor prognosis of patients with small hepatocellular carcinoma. Eur J Surg Oncol . 2018;44(7):1087–93. https://linkinghub.elsevier.com/retrieve/pii/S0748798318310230.

61.

Hu K, Chen F. Identification of significant pathways in gastric cancer based on protein-protein interaction networks and cluster analysis. Genet Mol Biol . 2012 ;35(3):701–8. http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572012000400023&lng=en&tlng=en.

62.

Li J, Ding Y, Li A. Identification of COL1A1 and COL1A2 as candidate prognostic factors in gastric cancer. World J Surg Oncol. 2016;14(1):297. https://doi.org/10.1186/s12957-016-1056-5.CrossRefPubMedPubMedCentral

63.

Yasui W, Oue N, Ito R, Kuraoka K, Nakayama H. Search for new biomarkers of gastric cancer through serial analysis of gene expression and its clinical implications. Cancer Sci. 2004;95(5):385–92. https://doi.org/10.1111/j.1349-7006.2004.tb03220.x.CrossRefPubMed

64.

Xu Y, Sengupta PK, Seto E, Smith BD. Regulatory factor for X-box family proteins differentially interact with histone deacetylases to repress collagen α2(I) gene ( COL1A2) expression. J Biol Chem. 2006;281(14):9260–70. https://doi.org/10.1074/jbc.M511724200.CrossRefPubMedPubMedCentral

65.

Fletcher CE, Sulpice E, Combe S, Shibakawa A, Leach DA, Hamilton MP, et al. Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer. Oncogene . 2019;38(28):5700–24. http://www.nature.com/articles/s41388-019-0823-5.

66.

Gyamfi J, Lee Y-H, Eom M, Choi J. Interleukin-6/STAT3 signalling regulates adipocyte induced epithelial-mesenchymal transition in breast cancer cells. Sci Rep . 2018;8(1):8859. http://www.nature.com/articles/s41598-018-27184-9.

67.

Bourguignon LYW, Singleton PA, Zhu H, Zhou B. Hyaluronan promotes signaling interaction between CD44 and the transforming growth factor β receptor I in metastatic breast tumor cells. J Biol Chem. 2002;277(42):39703–12. https://doi.org/10.1074/jbc.M204320200.CrossRefPubMed

68.

Jia S, Yang S, Du P, Gao K, Cao Y, Yao B, et al. Regulatory factor X1 downregulation contributes to monocyte chemoattractant protein-1 overexpression in CD14+ monocytes via epigenetic mechanisms in coronary heart disease. Front Genet. 2019. https://doi.org/10.3389/fgene.2019.01098/full.CrossRefPubMedPubMedCentral

69.

Li S, Lu J, Chen Y, Xiong N, Li L, Zhang J, et al. MCP-1-induced ERK/GSK-3β/Snail signaling facilitates the epithelial–mesenchymal transition and promotes the migration of MCF-7 human breast carcinoma cells. Cell Mol Immunol. 2017;14(7):621–30. http://www.nature.com/articles/cmi2015106.

70.

Sun Y, Fan X, Zhang Q, Shi X, Xu G, Zou C. Cancer-associated fibroblasts secrete FGF-1 to promote ovarian proliferation, migration, and invasion through the activation of FGF-1/FGFR4 signaling. Tumor Biol. 2017. https://doi.org/10.1177/1010428317712592.CrossRef

71.

Bai Y, Shang K, Chen H, Ding F, Wang Z, Liang C, et al. <scp>FGF</scp> -1/-3/ <scp>FGFR</scp> 4 signaling in cancer-associated fibroblasts promotes tumor progression in colon cancer through Erk and <scp>MMP</scp> -7. Cancer Sci. 2015;106(10):1278–87. https://doi.org/10.1111/cas.12745.CrossRefPubMedPubMedCentral

72.

Liu G, Ruan G, Huang M, Chen L, Sun P. Genome-wide DNA copy number profiling and bioinformatics analysis of ovarian cancer reveals key genes and pathways associated with distinct invasive/migratory capabilities. Aging (Albany NY). 2020;12(1):178–92. https://doi.org/10.18632/aging.102608.CrossRef

73.

Su JC, Tseng PH, Wu SH, Hsu CY, Tai WT, Li YS, et al. SC-2001 Overcomes STAT3-mediated Sorafenib Resistance through RFX-1/SHP-1 Activation in Hepatocellular Carcinoma. Neoplasia . 2014;16(7):595–605. https://linkinghub.elsevier.com/retrieve/pii/S1476558614000797.

74.

Ma HP, Chang HL, Bamodu OA, Yadav VK, Huang TY, Wu ATH, et al. Collagen 1A1 (COL1A1) Is a reliable biomarker and putative therapeutic target for hepatocellular carcinogenesis and metastasis. Cancers (Basel). 2019;11(6):786. https://www.mdpi.com/2072-6694/11/6/786.

75.

Smith G, Ng MTH, Shepherd L, Herrington CS, Gourley C, Ferguson MJ, et al. Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer. Br J Cancer . 2012;107(8):1327–36. http://www.nature.com/articles/bjc2012410.

76.

Yu T, Guo F, Yu Y, Sun T, Ma D, Han J, et al. Fusobacterium nucleatum Promotes chemoresistance to colorectal cancer by modulating autophagy. Cell . 2017 ;170(3):548–563.e16. https://linkinghub.elsevier.com/retrieve/pii/S0092867417308152.

77.

Grimmig T, Moench R, Kreckel J, Haack S, Rueckert F, Rehder R, et al. Toll like receptor 2, 4, and 9 signaling promotes autoregulative tumor cell growth and vegf/pdgf expression in human pancreatic cancer. Int J Mol Sci. 2016;17(12):2060. http://www.mdpi.com/1422-0067/17/12/2060.

78.

Cammarota R, Bertolini V, Pennesi G, Bucci EO, Gottardi O, Garlanda C, et al. The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker. J Transl Med. 2010;8(1):112. https://doi.org/10.1186/1479-5876-8-112.CrossRefPubMedPubMedCentral

79.

Cochaud S, Giustiniani J, Thomas C, Laprevotte E, Garbar C, Savoye A-M, et al. IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2. Sci Rep. 2013;3(1):3456. http://www.nature.com/articles/srep03456.

80.

Adcock IM, Caramori G. Transcription Factors. In: Asthma and COPD . Elsevier; 2009. p. 373–80. https://linkinghub.elsevier.com/retrieve/pii/B9780123740014000316.

81.

Ohashi Y, Ueda M, Kawase T, Kawakami Y, Toda M. Identification of an epigenetically silenced gene, RFX1, in human glioma cells using restriction landmark genomic scanning. Oncogene . 2004;23(47):7772–9. http://www.nature.com/articles/1208058.

82.

Rauscher GH, Kresovich JK, Poulin M, Yan L, Macias V, Mahmoud AM, et al. Exploring DNA methylation changes in promoter, intragenic, and intergenic regions as early and late events in breast cancer formation. BMC Cancer. 2015;15(1):816. https://doi.org/10.1186/s12885-015-1777-9.CrossRefPubMedPubMedCentral

83.

Zheng S, Houseman EA, Morrison Z, Wrensch MR, Patoka JS, Ramos C, et al. DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression. Neuro Oncol. 2011;13(3):280–9. https://doi.org/10.1093/neuonc/noq190.CrossRefPubMedPubMedCentral

84.

Wang W, Zhang R, Wang X, Wang N, Zhao J, Wei Z, et al. Suppression of KIF3A inhibits triple negative breast cancer growth and metastasis by repressing Rb-E2F signaling and epithelial-mesenchymal transition. Cancer Sci. 2020;111:1422.CrossRef

85.

Kang GM, Han YM, Ko HW, Kim J, Oh BC, Kwon I, et al. Leptin elongates hypothalamic neuronal cilia via transcriptional regulation and actin destabilization. J Biol Chem. 2015;290(29):18146–55. https://doi.org/10.1074/jbc.M115.639468.CrossRefPubMedPubMedCentral

86.

Lubelsky Y, Reuven N, Shaul Y. Autorepression of Rfx1 Gene Expression: Functional Conservation from Yeast to Humans in Response to DNA Replication Arrest. Mol Cell Biol. 2005;25(23):10665–73. https://mcb.asm.org/content/25/23/10665.

87.

Lubelsky Y, Shaul Y. Recruitment of the protein phosphatase-1 catalytic subunit to promoters by the dual-function transcription factor RFX1. Biochem Biophys Res Commun. 2019;509(4):1015–20. https://linkinghub.elsevier.com/retrieve/pii/S0006291X19300178.

88.

Liu, Yu-Chun, Chang, Kuo, Chen, Hsu, et al. Inhibition of protein phosphatase 1 stimulates noncanonical ER stress eIF2α activation to enhance fisetin-induced chemosensitivity in HDAC inhibitor-resistant hepatocellular carcinoma cells. Cancers (Basel) . 2019;11(7):918. https://www.mdpi.com/2072-6694/11/7/918.

89.

Agarwal V, Bell GW, Nam J-W, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife . 2015;4. https://elifesciences.org/articles/05005.

90.

Dillehay KL, Lu S, Dong Z. Antitumor effects of a novel small molecule targeting PCNA chromatin association in prostate cancer. Mol Cancer Ther. 2014;13(12):2817–26. https://doi.org/10.1158/1535-7163.MCT-14-0522.CrossRefPubMed

91.

Ritchie W, Rajasekhar M, Flamant S, Rasko JEJ. Conserved Expression Patterns Predict microRNA Targets. Ohler U, editor. PLoS Comput Biol . 2009;5(9):e1000513. Doi: https://doi.org/10.1371/journal.pcbi.1000513.

92.

Zhu HM, Jiang XS, Li HZ, Qian LX, Du MY, Lu ZW, et al. miR-184 Inhibits Tumor Invasion, Migration and Metastasis in Nasopharyngeal Carcinoma by Targeting Notch2. Cell Physiol Biochem . 2018;49(4):1564–76. https://www.karger.com/Article/FullText/493459.

93.

Wu GG, Li WH, He WG, Jiang N, Zhang GX, Chen W, et al. Mir-184 Post-Transcriptionally Regulates SOX7 Expression and Promotes Cell Proliferation in Human Hepatocellular Carcinoma. Villa E, editor. PLoS ONE . 2014;9(2):e88796. Doi: https://doi.org/10.1371/journal.pone.0088796.

94.

Wong TS, Liu XB, Wong BYH, Ng RWM, Yuen APW, Wei WI. Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res. 2008;14(9):2588–92. https://doi.org/10.1158/1078-0432.CCR-07-0666.CrossRefPubMed

95.

Liu L, Wang Q, Wang Q, Zhao X, Zhao P, Geng T, et al. Role of miR29c in goose fatty liver is mediated by its target genes that are involved in energy homeostasis and cell growth. BMC Vet Res. 2018;14:1–9.CrossRef

96.

Kondo Y, Shen L, Issa JPJ. Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell Biol. 2003;23(1):206–15. https://doi.org/10.1186/s12917-018-1653-3.CrossRefPubMedPubMedCentral

97.

Wang Y, Li Y, Sun J, Wang Q, Sun C, Yan Y, et al. Tumor-suppressive effects of miR-29c on gliomas. Neuroreport. 2013;24(12):637–45. http://journals.lww.com/00001756-201308210-00001.

98.

Wang Y, Li Y, Sun J, Wang Q, Sun C, Yan Y, et al. Tumor-suppressive effects of miR-29c on gliomas. NeuroReport. 2013;24:637.CrossRef

99.

Zhou K, Yu Z, Yi S, Li Z, An G, Zou D, et al. miR-29c down-regulation is associated with disease aggressiveness and poor survival in Chinese patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2014;55(7):1544–50. https://doi.org/10.3109/10428194.2013.855308.CrossRefPubMed

100.

Chen B, Song G, Liu M, Qian L, Wang L, Gu H, et al. Inhibition of miR-29c promotes proliferation, and inhibits apoptosis and differentiation in P19 embryonic carcinoma cells. Mol Med Rep. 2016;13(3):2527–35. https://doi.org/10.3892/mmr.2016.4832.CrossRefPubMedPubMedCentral

101.

Guo Y, Zhao M, Lu Q. Transcription factor RFX1 is ubiquitinated by E3 ligase STUB1 in systemic lupus erythematosus. Clin Immunol. 2016;169:1–7. http://linkinghub.elsevier.com/retrieve/pii/S152166161630095X.

102.

Udeshi ND, Svinkina T, Mertins P, Kuhn E, Mani DR, Qiao JW, et al. Refined preparation and use of anti-diglycine remnant (K-ε-GG) antibody enables routine quantification of 10,000s of ubiquitination sites in single proteomics experiments. Mol Cell Proteomics. 2013;12(3):825–31. https://doi.org/10.1074/mcp.O112.027094.CrossRefPubMed

103.

Sun A, Li C, Chen R, Huang Y, Chen Q, Cui X, et al. GSK-3β controls autophagy by modulating LKB1-AMPK pathway in prostate cancer cells. Prostate. 2016;76(2):172–83. https://doi.org/10.1002/pros.23106.CrossRefPubMed

104.

Monaco E, Bionaz M, Rodriguez-Zas S, Hurley WL, Wheeler MB. Transcriptomics Comparison between Porcine Adipose and Bone Marrow Mesenchymal Stem Cells during In Vitro Osteogenic and Adipogenic Differentiation. Beltrami AP, editor. PLoS One . 2012;7(3):e32481. Doi:https://doi.org/10.1371/journal.pone.0032481.

105.

Coppola JA, Cole MD. Constitutive c-myc oncogene expression blocks mouse erythroleukaemia cell differentiation but not commitment. Nature. 1986;

106.

Elbadawy M, Usui T, Yamawaki H, Sasaki K. Emerging Roles of C-Myc in Cancer Stem Cell-Related Signaling and Resistance to Cancer Chemotherapy: A Potential Therapeutic Target Against Colorectal Cancer. Int J Mol Sci . 2019;20(9):2340. https://www.mdpi.com/1422-0067/20/9/2340.

107.

Zhang H, Wang P, Lu M, Zhang S, Zheng L. c-Myc maintains the self-renewal and chemoresistance properties of colon cancer stem cells. Oncol Lett. 2019. https://doi.org/10.3892/ol.2019.10081.CrossRefPubMedPubMedCentral

108.

Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature . 1983 ;304(5927):596–602. http://www.nature.com/articles/304596a0.

109.

Chung SY, Chen YH, Lin PR, Chao TC, Su JC, Shiau CW, et al. Two novel SHP-1 agonists, SC-43 and SC-78, are more potent than regorafenib in suppressing the in vitro stemness of human colorectal cancer cells. Cell Death Discov . 2018;4(1):82. http://www.nature.com/articles/s41420-018-0084-z.

110.

Chen L, Smith L, Johnson MR, Wang K, Diasio RB, Smith JB. Activation of protein kinase C induces nuclear translocation of RFX1 and down-regulates c-myc via an intron 1 X box in undifferentiated leukemia HL-60 cells. J Biol Chem . 2000;275(41):32227–33. http://www.ncbi.nlm.nih.gov/pubmed/10918054.

111.

Tahara E, Kadara H, Lacroix L, Lotan D, Lotan R. Activation of Protein Kinase C by Phorbol 12-Myristate 13-Acetate suppresses the growth of lung cancer cells through KLF6 induction. Cancer Biol Ther. 2009;8(9):801–7. https://doi.org/10.4161/cbt.8.9.8186.CrossRefPubMed

112.

Takashiba S, Van Dyke TE, Amar S, Murayama Y, Soskolne AW, Shapira L. Differentiation of monocytes to macrophages primes cells for lipopolysaccharide stimulation via accumulation of cytoplasmic nuclear factor kappaB. Infect Immun . 1999;67(11):5573–8. http://www.ncbi.nlm.nih.gov/pubmed/10531202.

113.

Kurie JM, Younes A, Miller WH, Burchert M, Chiu CF, Kolesnick R, et al. Retinoic acid stimulates the protein kinase C pathway before activation of its beta-nuclear receptor during human teratocarcinoma differentiation. Biochim Biophys Acta . 1993 ;1179(2):203–7. http://www.ncbi.nlm.nih.gov/pubmed/8218362.

114.

Cheng K, Sun H, Zhang M, Shen L. [Overexpression of lentivirus RFX1 and its inhibitory effect on proliferation of glioblastoma cells]. Zhong Nan Da Xue Xue Bao Yi Xue Ban . 2016;41(11):1117–23. http://europepmc.org/abstract/MED/27932754.

115.

Zhao M, Wu X, Zhang Q, Luo S, Liang G, Su Y, et al. RFX1 regulates CD70 and CD11a expression in lupus T cells by recruiting the histone methyltransferase SUV39H1. Arthritis Res Ther. 2010;12(6):R227. https://doi.org/10.1186/ar3214.CrossRefPubMedPubMedCentral

116.

Liu L, Yin B, Yi Z, Liu X, Hu Z, Gao W, et al. Breast cancer stem cells characterized by CD70 expression preferentially metastasize to the lungs. Breast Cancer. 2018;25(6):706–16. https://doi.org/10.1007/s12282-018-0880-6.CrossRefPubMed

117.

Orian-Rousseau V, Schmitt M. CD44 regulates Wnt signaling at the level of LRP6. Mol Cell Oncol. 2015;2(3):e995046. https://doi.org/10.4161/23723556.2014.995046.CrossRefPubMedPubMedCentral

118.

Zhang S, Li Y, Wu Y, Shi K, Bing L, Hao J. Wnt/β-catenin signaling pathway upregulates c-Myc expression to promote cell proliferation of P19 teratocarcinoma cells. Anat Rec Adv Integr Anat Evol Biol. 2012;295(12):2104–13. https://doi.org/10.1002/ar.22592.CrossRef

119.

Riether C, Schürch CM, Flury C, Hinterbrandner M, Drück L, Huguenin AL, et al. Tyrosine kinase inhibitor–induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling. Sci Trans Med. 2015;7(298):298ra119. https://doi.org/10.1126/scitranslmed.aab1740.CrossRef

120.

Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduction Targeted Therapy. 2020;5:1–35.CrossRef

121.

Weaver AN, Burch MB, Cooper TS, Della Manna DL, Wei S, Ojesina AI, et al. Notch signaling activation is associated with patient mortality and increased FGF1-mediated invasion in squamous cell carcinoma of the oral cavity. Mol Cancer Res. 2016;14(9):883–91. https://doi.org/10.1158/1541-7786.MCR-16-0114.CrossRefPubMed

122.

Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, et al. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol . 2015;12(8):445–64. http://www.nature.com/articles/nrclinonc.2015.61.

123.

Capaccione KM, Pine SR. The Notch signaling pathway as a mediator of tumor survival. Carcinogenesis. 2013;34:1420.CrossRef

124.

Yu Z, Pestell TG, Lisanti MP, Pestell RG. Cancer stem cells. Int J Biochem Cell Biol . 2012;44(12):2144–51. https://linkinghub.elsevier.com/retrieve/pii/S1357272512003007.

125.

Lungu G, Covaleda L, Mendes O, Martini-Stoica H, Stoica G. FGF-1-induced matrix metalloproteinase-9 expression in breast cancer cells is mediated by increased activities of NF-κB and activating protein-1. Mol Carcinog. 2008;47(6):424–35. https://doi.org/10.1002/mc.20398.CrossRefPubMed

126.

Peng D, Tanikawa T, Li W, Zhao L, Vatan L, Szeliga W, et al. Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling. Cancer Res . 2016;76(11):3156–65. https://linkinghub.elsevier.com/retrieve/pii/S109727651200740X.

127.

Ferrando AA. The role of NOTCH1 signaling in T-ALL. Hematology . 2009;2009(1):353–61. https://ashpublications.org/hematology/article/2009/1/353/19869/The-role-of-NOTCH1-signaling-in-TALL.

128.

Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A, et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci. 2006;103(48):18261–6. https://doi.org/10.1073/pnas.0606108103.CrossRefPubMed

129.

Tamagawa Y, Ishimura N, Uno G, Yuki T, Kazumori H, Ishihara S, et al. Notch signaling pathway and Cdx2 expression in the development of Barrett’s esophagus. Lab Investig . 2012;92(6):896–909. http://www.nature.com/articles/labinvest201256.

130.

Chen YC, Tsai CL, Wei YH, Wu YT, Hsu WT, Lin HC, et al. ATOH1/RFX1/RFX3 transcription factors facilitate the differentiation and characterisation of inner ear hair cell-like cells from patient-specific induced pluripotent stem cells harbouring A8344G mutation of mitochondrial DNA. Cell Death Dis . 2018;9(4):437. http://www.nature.com/articles/s41419-018-0488-y.

131.

Duan L, Maki CG. The IGF-1R/AKT pathway determines cell fate in response to p53. Transl Cancer Res . 2016;5(6):664–75. http://tcr.amegroups.com/article/view/9527/9784.

132.

Zhang M, Liu J, Li M, Zhang S, Lu Y, Liang Y, et al. Insulin-like growth factor 1/insulin-like growth factor 1 receptor signaling protects against cell apoptosis through the PI3K/AKT pathway in glioblastoma cells. Exp Ther Med. 2018;

133.

Lin L, Liu A, Peng Z, Lin H-J, Li P-K, Li C, et al. STAT3 Is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res. 2011;71(23):7226–37. https://doi.org/10.1158/0008-5472.CAN-10-4660.CrossRefPubMedPubMedCentral

134.

Akhurst RJ, Hata A. Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov . 2012;11(10):790–811. http://www.nature.com/articles/nrd3810.

135.

Liu Y, Gao X, Wang S, Yuan X, Pang Y, Chen J, et al. Cancer Stem Cells are Regulated by STAT3 Signalling in Wilms Tumour. J Cancer . 2018;9(8):1486–99. http://www.jcancer.org/v09p1486.htm.

136.

Peng D, Tanikawa T, Li W, Zhao L, Vatan L, Szeliga W, et al. Myeloid-derived suppressor cells endow stem-like qualities to breast cancer cells through IL6/STAT3 and NO/NOTCH cross-talk signaling. Cancer Res. 2016;

137.

Gotovac JR, Fujihara KM, Phillips WA, Clemons NJ. TGF-beta signaling and its targeted therapy in gastrointestinal cancers. Discov Med . 2018;26(142):103–12. https://www.discoverymedicine.com/Jovana-R-Gotovac/2018/09/tgf-beta-signaling-and-its-targeted-therapy-in-gastrointestinal-cancers/.

138.

Colland F. Functional proteomics mapping of a human signaling pathway. Genome Res. 2004;14(7):1324–32. https://doi.org/10.1101/gr.2334104.CrossRefPubMedPubMedCentral

139.

Feng C, Zuo Z. Regulatory factor X1-induced down-regulation of transforming growth factor β2 transcription in human neuroblastoma cells. J Biol Chem. 2012;287(27):22730–9. https://doi.org/10.1074/jbc.M111.338590.CrossRefPubMedPubMedCentral

140.

Bragado P, Estrada Y, Sosa MS, Schewe DM, Capobianco C, Moore K, et al. Abstract 5234: Microenvironmental signals dictate disseminated tumor cells (DTCs) fate through regulation of TGFβII and p38α. In: Tumor Biology . American Association for Cancer Research; 2012. p. 5234–5234. http://cancerres.aacrjournals.org/lookup/doi/https://doi.org/10.1158/1538-7445.AM2012-5234.

141.

Sun TM, Wang YC, Wang F, Du JZ, Mao CQ, Sun CY, et al. Cancer stem cell therapy using doxorubicin conjugated to gold nanoparticles via hydrazone bonds. Biomaterials . 2014;35(2):836–45. https://linkinghub.elsevier.com/retrieve/pii/S0142961213012222.

142.

Sun R, Liu Y, Li SY, Shen S, Du XJ, Xu CF, et al. Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells. Biomaterials . 2015;37:405–14. https://linkinghub.elsevier.com/retrieve/pii/S0142961214010655.

143.

Cheng Z, He Z, Cai Y, Zhang C, Fu G, Li H, et al. Conversion of hepatoma cells to hepatocyte-like cells by defined hepatocyte nuclear factors. Cell Res . 2019;29(2):124–35. http://www.nature.com/articles/s41422-018-0111-x.

144.

Best SA, Nwaobasi AN, Schmults CD, Ramsey MR. CCAR2 Is required for proliferation and tumor maintenance in human squamous cell carcinoma. J Invest Dermatol. 2017;

145.

Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol . 2019;16(10):589–604. http://www.ncbi.nlm.nih.gov/pubmed/31439937.

146.

Wang J, Jia J, Chen R, Ding S, Xu Q, Zhang T, et al. RFX1 participates in doxorubicin-induced hepatitis B virus reactivation. Cancer Med. 2018;7(5):2021–33. https://doi.org/10.1002/cam4.1468.CrossRefPubMedPubMedCentral

147.

Ori A, Zauberman A, Doitsh G, Paran N, Oren M, Shaul Y. p53 binds and represses the HBV enhancer: an adjacent enhancer element can reverse the transcription effect of p53. EMBO J. 1998;17(2):544–53. https://doi.org/10.1093/emboj/17.2.544.CrossRefPubMedPubMedCentral

148.

Bushweller JH. Targeting transcription factors in cancer—from undruggable to reality. Nat Rev Cancer. 2019;19(11):611–24. https://doi.org/10.1038/s41568-019-0196-7.CrossRefPubMed

149.

Cohen PTW. Protein phosphatase 1–targeted in many directions. J Cell Sci . 2002 ;115(2):241 LP – 256. http://jcs.biologists.org/content/115/2/241.abstract.

150.

Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013. https://doi.org/10.1126/scisignal.2004088.CrossRefPubMedPubMedCentral

151.

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data: Figure 1. Cancer Discov. 2012;2(5):401–4. https://doi.org/10.1158/2159-8290.CD-12-0095.CrossRef

152.

OrianRousseau V. CD44 Acts as a Signaling Platform Controlling Tumor Progression and Metastasis. Front Immunol. 2015. https://doi.org/10.3389/fimmu.2015.00154/abstract.CrossRef

153.

Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway. J Exp Med. 2009;206(7):1457–64. https://rupress.org/jem/article/206/7/1457/40324/IL17-can-promote-tumor-growth-through-an-IL6Stat3.

154.

Sengupta P, Xu Y, Wang L, Widom R, Smith BD. Collagen α1(I) Gene ( COL1A1) Is Repressed by RFX Family. J Biol Chem. 2005;280(22):21004–14. https://doi.org/10.1074/jbc.M413191200.CrossRefPubMedPubMedCentral

155.

Sengupta PK, Fargo J, Smith BD. The RFX family interacts at the collagen (COL1A2) start site and represses transcription. J Biol Chem. 2002;277(28):24926–37. https://doi.org/10.1074/jbc.M111712200.CrossRefPubMed

156.

Liu M, Lee BH, Mathews MB. Involvement of RFX1 protein in the regulation of the human proliferating cell nuclear antigen promoter. J Biol Chem. 1999;274(22):15433–9. https://doi.org/10.1074/jbc.274.22.15433.CrossRefPubMed

157.

Lee BH, Liu M, Mathews MB. Regulation of the Human Proliferating Cell Nuclear Antigen Promoter by the Adenovirus E1A-Associated Protein p107. J Virol . 1998;72(2):1138–45. https://jvi.asm.org/content/72/2/1138.

158.

Ma K, Zheng S, Zuo Z. The transcription factor regulatory factor X1 increases the expression of neuronal glutamate transporter type 3. J Biol Chem. 2006;281(30):21250–5. https://doi.org/10.1074/jbc.M600521200.CrossRefPubMed

159.

Jiang J, Zhang N, Shiba H, Li L, Wang Z. Spermatogenesis Associated 4 Promotes Sertoli Cell Proliferation Modulated Negatively by Regulatory Factor X1. Rouault J-P, editor. PLoS ONE . 2013;8(10):e75933. https://doi.org/10.1371/journal.pone.0075933.

160.

Zhang Y, Chen B, Li YP, Chen J, Lou GY, Chen M, et al. Transcriptional regulation of the human gene coding for proline-rich nuclear receptor coactivator (PNRC) by regulatory factor X (RFX1). Mol Biol. 2009;43(1):68–75. https://doi.org/10.1134/S0026893309010099.CrossRef

161.

Tammimies K, Bieder A, Lauter G, Sugiaman-Trapman D, Torchet R, Hokkanen M, et al. Ciliary dyslexia candidate genes DYX1C1 and DCDC2 are regulated by regulatory factor X (RFX) transcription factors through X-box promoter motifs. FASEB J. 2016;30(10):3578–87. https://doi.org/10.1096/fj.201500124RR.CrossRefPubMedPubMedCentral

162.

Norquay LD, Yang X, Sheppard P, Gregoire S, Dodd JG, Reith W, et al. RFX1 and NF-1 associate with p sequences of the human growth hormone locus in pituitary chromatin. Mol Endocrinol. 2003;17(6):1027–38. https://doi.org/10.1210/me.2003-0025.CrossRefPubMed

163.

Boito R, Menniti M, Amato R, Palmieri C, Marinaro C, Iuliano R, et al. RFX-1, a putative alpha Adducin interacting protein in a human kidney library. FEBS Lett. 2005;579(28):6439–43. https://doi.org/10.1016/j.febslet.2005.10.040.CrossRefPubMed

Keynote webinar | Spotlight on medication adherence

Springer Medicine

RFX1: a promising therapeutic arsenal against cancer

Abstract

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Anti-cancer properties of quercetin in osteosarcoma

Targeting SNHG3/miR-186-5p reverses the increased m6A level caused by platinum treatment through regulating METTL3 in esophageal cancer

Systematic analysis of the expression and prognosis relevance of FBXO family reveals the significance of FBXO1 in human breast cancer

NAT10 as a potential prognostic biomarker and therapeutic target for HNSCC

Pan-cancer analysis combined with experiments predicts CTHRC1 as a therapeutic target for human cancers

The immune‐related biomarker TEK inhibits the development of clear cell renal cell carcinoma (ccRCC) by regulating AKT phosphorylation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer